Uncategorized
Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.